Hepatitis B Vaccine Market to Reach USD 12.7 Billion by 2035, Growing at 7.1% CAGR | Panacea Biotec, Pfizer Inc., Sanofi

According to the report, the hepatitis B vaccine market is anticipated to grow from USD 6.4 Billion in 2025 to USD 12.7 Billion in 2035 at a CAGR of 7.1% during the forecast. The hepatitis B vaccine market continues to grow, driven by improved immunization coverage programs and the increased utilization of combination vaccines that can simplify childhood vaccination schedules.

Additionally, there is an ongoing collaboration with public health partners in Africa and Southeast Asia, to improve vaccine coverage in rural areas that do not have cold chain supply. Pilot projects are also exploring use of digital applications to enhance tracking and adherence of vaccinations.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Hepatitis B Vaccine Market Research Report: https://marketgenics.co/press-releases/hepatitis-b-vaccine-market-37646

Regional Analysis of Global Hepatitis B Vaccine Market

Presently, North America is still the dominant region of the C-arm market, as it possesses advanced level of healthcare infrastructures, and the greatest number of surgical procedures and a strong adoption of mobile imaging technology. More specifically, with steady spending in outpatient surgical centers in the U.S., alongside increased demand for minimally invasive surgeries, it will continue to be the predominant area. Following North America is Europe, with Germany, the U.K., and France gradually adopting AI-based imaging tools into operating rooms.
Asia-Pacific is the fastest-growing region, aided by improved access to healthcare, increasing spending on medical equipments and more private hospitals across India, China, and Southeast Asia.

Lastly, although growth appears slow in Latin America and Africa to date, demand is growing as government spending increases in basic imaging infrastructure and rural healthcare. Limited C-arm use in these markets is being augmented with local manufacturing and purchasing of refurbished machines, together increasing accessibility to Hepatitis B Vaccine in developing regions.

Key players in the global hepatitis B vaccine market include prominent companies such as Bharat Biotech, Biological E. Limited, Chengdu Institute of Biological Products Co., Ltd., CSL Limited (Seqirus), Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline plc, Hualan Biological, Engineering Inc., Indian Immunologicals Ltd., LG Chem, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec, Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., VBI Vaccines Inc., Walvax Biotechnology Co., Ltd., Zydus Lifesciences Limited, and other key players along with several other key players contributing to market growth through innovation, strategic partnerships, and global expansion.

To know more about the Hepatitis B Vaccine Market - Download our Sample Report: https://marketgenics.co/download-report-sample/hepatitis-b-vaccine-market-37646

Key Driver, Restraint, and Growth Opportunity Defining the Global Hepatitis B Vaccine Market

The market for hepatitis B vaccines is supported by global vaccination initiatives and public health programs intended to lessen the prevalence of hepatitis B infection, as well as knowledge of the long duration of the complications of the disease and increasing demand in developing nations.

Several public health challenges affect the market, including vaccine hesitancy, the high costs associated with vaccination programs and unequal availability of health care in developing nations in which hepatitis B tends to have a higher prevalence. Additional challenges come from the reliance on vaccine cold-chain logistics for vaccines to retain stability, and logistical procurement processes.

Further, increased stable, single-dose, and combination vaccines have created numerous growth opportunities, particularly within the context of enhancing vaccination coverage for the public good through public-private partnerships and adult immunization rates.

Buy Now: https://marketgenics.co/buy/hepatitis-b-vaccine-market-37646

Recent Development and Strategic Overview:

In April 2025, Sanofi Pasteur launched a new, improved Hexacima pediatric multi-dose vaccine that contains hepatitis B, DTaP, IPV, Hib, and hepatitis A. The new Hexacima vaccine also has a prefilled, ready-to-use syringe format, resulting in fewer preparation steps, less potential for dosing errors by healthcare workers. The provided pick-you-up immunization setup is a simplified one, with full coverage for immunization and a more user-friendly product. Hexacima is particularly suited for busy clinics and high-volume vaccination events.

In August 2025, Dynavax announced record quarterly revenue of USD 91.9 million from its two-dose HEPLISAV-B adult hepatitis B vaccine, a 31% increase over the same quarter in 2024. The company indicated HEPLISAV-B now occupies approximately 45% of the U.S. adult vaccine market due to HEPLISAV-B's unique one-month dosing regimen, and its vigorous adoption throughout retail and health systems.

Get a preview of our Hepatitis B Vaccine Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/hepatitis-b-vaccine-market-37646

Key Trend: Hepatitis B Vaccine Market Enhancing Tracking and Outreach through AI and Digital Tools

A significant trend in this market is the implementation of artificial intelligence (AI) and digital platforms to keep track of vaccinations and enhance outreach. The presence of mobile health applications with digital records is an important development in tracking vaccine coverage, particularly in remote and rural areas. Utilizing data analytics tools, governments can determine the gap in immunization and run focused campaigns.

Digitalization is also offering higher levels of automation for cold chain management which is aiding the prevention of vaccine spoilage and delays in vaccine delivery. Various regions are beginning to introduce AI, to predict outbreaks of disease and prepare. Furthermore, there is a real intention to place Hepatitis B vaccinations with other vaccines combined for healthcare systems to perform immunization better.

Thus, improved access to vaccinations, better vaccine planning, and vaccine effectiveness is being offered.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.